Product Pipeline


Xenon is focused on advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.



Preclinical
Phase 1
Phase 2
Phase 3
Approved

XEN1101

for Focal Onset Seizures (FOS)
X-TOLE2/3 Clinical Trial

XEN1101

for Primary Generalized Tonic-Clonic Seizures (PGTCS)​
X-ACKT Clinical Trial

XEN1101

for Major Depressive Disorder (MDD)
X-NOVA Clinical trial

XEN1101

for MDD
Investigator-led Phase 2 POC study Collaboration with Mount Sinai

NBI-921352

for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences


Medical Affairs

Learn more about our ongoing clinical trials

View Medical Affairs
Publications

See publications related to our clinical development candidates

View Publications
Partners

Find out more about collaborating with Xenon

View Partners